BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38212245)

  • 1. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
    Lee DJ; El-Khoury H; Tramontano AC; Alberge JB; Perry J; Davis MI; Horowitz E; Redd R; Sakrikar D; Barnidge D; Perkins MC; Harding S; Mucci L; Rebbeck TR; Ghobrial IM; Marinac CR
    Blood Adv; 2024 Apr; 8(7):1737-1746. PubMed ID: 38212245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
    El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
    Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
    Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
    Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
    Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
    Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.
    Landgren O; Rajkumar SV; Pfeiffer RM; Kyle RA; Katzmann JA; Dispenzieri A; Cai Q; Goldin LR; Caporaso NE; Fraumeni JF; Blot WJ; Signorello LB
    Blood; 2010 Aug; 116(7):1056-9. PubMed ID: 20421448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
    Iwanaga M; Tomonaga M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
    Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
    Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
    Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
    Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
    Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
    JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima.
    Fujimura K; Sugiyama A; Akita T; Ohisa M; Nagashima S; Katayama K; Maeda R; Tanaka J
    Int J Hematol; 2021 Apr; 113(4):576-585. PubMed ID: 33389658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
    Greenberg AJ; Rajkumar SV; Vachon CM
    Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.